Advertisement

Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success

  • Dan Călugăru
  • Mihai CălugăruEmail author
Letter to the Editor

Dear Editor:

We would like to address several challenges that arise from the study by Laiginhas et al. [1].

The study was retrospectively conducted with a short follow-up.

There was a selection bias attributable to inclusion in the study of patients with all types of diabetic retinopathy (mild, moderate, and severe nonproliferative and proliferative diabetic retinopathy) as well as to pooling together of data from patients who were treated by different retina specialists [2]. Additionally, nothing was stated about the existence or otherwise of a washout period, which is essential between the two periods of treatments in terms of aliased effects. In the absence of a real washout period, the impact of the significant carryover effects of the bevacizumab (Avastin, Genentech, Inc., San Francisco, CA, USA) therapy may be confounded with direct effects of the aflibercept (Eylea, Regeneron, Tarrytown, NY, USA) treatment because these effects could not be estimated separately; therefore,...

Notes

Authors’ contribution

All authors have completed and submitted the ICMJE form for disclosure of potential conflicts of interest. Both authors (D.C and M.C) were involved in the design and conduct of the study; collection, management, analysis, and interpretation of the data; and preparation, review, or approval of the manuscript.

The authors have full control over the primary data and they agree to allow Graefe’s Archive for Clinical and Experimental Ophthalmology to review their data if requested.

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

References

  1. 1.
    Laiginhas R, Silva MI, Rosas V et al (2018) Aflibercept in diabetic macular edema refractory to previous bevacizumab: outcomes and predictors of success. Graefes Arch Clin Exp Ophthalmol 256:83–89CrossRefPubMedGoogle Scholar
  2. 2.
    Călugăru D, Călugăru M (2018) Early response to intravitreal dexamethasone implant therapy in diabetic macular edema may predict visual outcome. Am J Ophthalmol 186:164–165CrossRefPubMedGoogle Scholar
  3. 3.
    Călugăru D, Călugăru M (2017) Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema. Graefes Arch Clin Exp Ophthalmol 255:1451–1452CrossRefPubMedGoogle Scholar
  4. 4.
    Călugăru D, Călugăru M (2017) Aflibercept for diabetic macular edema in eyes previously treated with ranibizumab and/or bevacizumab may further improve macular thickness. Ophthalmic Surg Lasers Imaging Retina 48:528–529CrossRefPubMedGoogle Scholar
  5. 5.
    Freund KB, Korobelnik JF, Deveny R et al (2015) Treat-and-extend regimens with anti-VEGF agents in retinal diseases. Retina 35:1489–1506CrossRefPubMedGoogle Scholar
  6. 6.
    Gover S, Murthy RK, Brar VS, Chalam KV (2009) Normative data for macular thickness by high-definition spectral-domain optical coherence tomography (Spectralis). Am J Ophthalmol 148:266–271CrossRefGoogle Scholar
  7. 7.
    Călugăru D, Călugăru M (2017) Short-term outcomes of aflibercept therapy for diabetic macular edema in patients with incomplete response to ranibizumab and/or bevacizumab. Ophthalmic Surg Lasers Imaging Retina 48:280CrossRefPubMedGoogle Scholar
  8. 8.
    Călugăru D, Călugăru M (2017) Real-world outcomes of ranibizumab treatment for diabetic macular edema in a United Kingdom National Health Service Setting. Am J Ophthalmol 174:175–176CrossRefPubMedGoogle Scholar
  9. 9.
    Călugăru D, Călugăru M (2016) Conversion to aflibercept after prior anti-VEGF therpy for persistent diabetic macular edema. Am J Ophthalmol 168:290–291CrossRefPubMedGoogle Scholar
  10. 10.
    Călugăru D, Călugăru M (2015) Intravitreal bevacizumab in acute central/hemicentral retinal vein occlusions: three-year results of a prospective clinical study. J Ocul Pharmacol Ther 31:78–86CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of OphthalmologyUniversity of Medicine Cluj-NapocaCluj-NapocaRomania

Personalised recommendations